Public perceptions of high-cost cancer drugs and the implications for reimbursement decisions

Youran Noh and Kyung-Bok Son ()
Additional contact information
Youran Noh: College of Pharmacy, Hanyang University
Kyung-Bok Son: College of Pharmacy, Hanyang University

Health Economics Review, 2025, vol. 15, issue 1, 1-11

Abstract: Abstract Background Reimbursing high-cost cancer drugs presents challenges in managing uncertainty, setting appropriate prices, and controlling pharmaceutical expenditures. We examined the perspectives of the South Korean public on high-cost cancer drugs and policy options to improve reimbursement for these treatments. Methods We conducted a self-rated, web-based survey from November to December 2023. We used a quota sampling method based on South Korean census data to recruit study participants. The questionnaire comprised four sections: socio-demographics, definitions of high-cost cancer drugs and reasons for their reimbursement, uncertainties associated with high-cost cancer drugs, and policy options to improve reimbursement for these treatments. Results Of the 11,974 invitations sent, 1,000 participants completed the survey, resulting in a response rate of 8.35%. Three-quarters of the respondents agreed or strongly agreed that high-cost cancer drugs should be reimbursed. More than 70% accepted the need for price negotiations, even if they lead to drug withdrawals or delays in reimbursement decisions. A similar proportion agreed that new policy options, such as dual pricing and additional funding, should be introduced with caution. Conclusion The South Korean public perceives the reimbursement of high-cost cancer drugs as both a human rights measure and a government responsibility. However, they support reimbursement only when they are confident that the drug is safe, effective, and cost-effective.

Keywords: High-cost cancer drug; New drug; Policy options; Reimbursement; South Korea (search for similar items in EconPapers)
Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1186/s13561-025-00659-y Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:hecrev:v:15:y:2025:i:1:d:10.1186_s13561-025-00659-y

Ordering information: This journal article can be ordered from
http://www.springer.com/journal/13561

DOI: 10.1186/s13561-025-00659-y

Access Statistics for this article

Health Economics Review is currently edited by J. Matthias Graf von der Schulenburg

More articles in Health Economics Review from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().